8QWP

Structure of p53 cancer mutant Y236C

8QWP の概要

• エントリーDOI: 10.2210/pdb8qwp/pdb
• 分子名称: Cellular tumor antigen p53, ZINC ION, L(+)-TARTARIC ACID, ... (5 entities in total)
• 機能のキーワード: tumor suppressor, transcription factor, cancer mutation, protein stability, conformational mutant, dna binding protein
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 49616.75

構造登録者

Balourdas, D.I.,Knapp, S.,Joerger, A.C.,Structural Genomics Consortium (SGC) (登録日: 2023-10-19, 公開日: 2024-06-19)

主引用文献

Balourdas, D.I.,Markl, A.M.,Kramer, A.,Settanni, G.,Joerger, A.C.
Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators.
Cell Death Dis, 15:408-408, 2024

PubMed Abstract: The cavity-creating p53 cancer mutation Y220C is an ideal paradigm for developing small-molecule drugs based on protein stabilization. Here, we have systematically analyzed the structural and stability effects of all oncogenic Tyr-to-Cys mutations (Y126C, Y163C, Y205C, Y220C, Y234C, and Y236C) in the p53 DNA-binding domain (DBD). They were all highly destabilizing, drastically lowering the melting temperature of the protein by 8-17 °C. In contrast, two non-cancerous mutations, Y103C and Y107C, had only a moderate effect on protein stability. Differential stabilization of the mutants upon treatment with the anticancer agent arsenic trioxide and stibogluconate revealed an interesting proximity effect. Crystallographic studies complemented by MD simulations showed that two of the mutations, Y234C and Y236C, create internal cavities of different size and shape, whereas the others induce unique surface lesions. The mutation-induced pockets in the Y126C and Y205C mutant were, however, relatively small compared with that of the already druggable Y220C mutant. Intriguingly, our structural studies suggest a pronounced plasticity of the mutation-induced pocket in the frequently occurring Y163C mutant, which may be exploited for the development of small-molecule stabilizers. We point out general principles for reactivating thermolabile cancer mutants and highlight special cases where mutant-specific drugs are needed for the pharmacological rescue of p53 function in tumors.

PubMed: 38862470
DOI: 10.1038/s41419-024-06739-x

実験手法

X-RAY DIFFRACTION (2.1 Å)